Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 210 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Athyros, Vasilios G  [Clear All Filters]
Journal Article
Athyros, V. G., Papageorgiou A., Athyrou V., & Karagiannis A. (2017).  Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J et al. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Tre. J Clin Lipidol. 11(1), 306-307.
Mitsiou, E. K., Tziomalos K., Anagnostis P., Karagiannis A., & Athyros V. G. (2009).  Multifactorial intervention for the prevention of vascular complications of type 2 diabetes.. Hellenic J Cardiol. 50(6), 445-8.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations.. Angiology. 64(8), 572-5.
Tziomalos, K., Athyros V. G., Paschos P., & Karagiannis A. (2015).  Nonalcoholic fatty liver disease and statins.. Metabolism. 64(10), 1215-23.
Athyros, V. G., Polyzos S. A., Kountouras J., Katsiki N., Anagnostis P., Doumas M., et al. (2019).  Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block.. Curr Vasc Pharmacol.
Athyros, V. G., Tziomalos K., Katsiki N., & Mikhailidis D. P. (2014).  Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors.. Curr Pharm Des. 20(40), 6215-9.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Off target effects of statins shape total mortality?. J Drug Assess. 5(1), 4-5.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2008).  Omega-3 fatty acids: how can they be used in secondary prevention?. Curr Atheroscler Rep. 10(6), 510-7.
Kakafika, A. I., Mikhailidis D. P., Wierzbicki A. S., Karagiannis A., & Athyros V. G. (2007).  PCI and stable coronary heart disease--COURAGE to change our minds?. Curr Vasc Pharmacol. 5(3), 173-4.
Doumas, M., Imprialos K. P., Stavropoulos K., & Athyros V. G. (2018).  Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. J Clin Hypertens (Greenwich). 20(3), 469-471.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2014).  Peripheral artery disease in patients with type 2 diabetes.. J Diabetes Complications. 28(6), 912.
Filippatos, T. D., Athyros V. G., & Elisaf M. S. (2014).  The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].. Expert Opin Drug Metab Toxicol. 10(6), 787-812.
Karagiannis, A., Mikhailidis D. P., Athyros V. G., & Harsoulis F. (2007).  Pheochromocytoma: an update on genetics and management.. Endocr Relat Cancer. 14(4), 935-56.
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Pleiotropic effects of statins--clinical evidence.. Curr Pharm Des. 15(5), 479-89.
Imprialos, K. P., Stavropoulos K., Doumas M., Skalkou A., Zografou I., & Athyros V. G. (2018).  The potential role of statins in treating liver disease.. Expert Rev Gastroenterol Hepatol. 12(4), 331-339.
Katsiki, N., Doumas M., Athyros V. G., & Karagiannis A. (2014).  Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit.. Expert Rev Cardiovasc Ther. 12(3), 295-6.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention.. Circ J. 77(5), 1348.
Athyros, V. G., Ganotakis E. S., Elisaf M. S., Liberopoulos E. N., Goudevenos I. A., & Karagiannis A. (2007).  Prevalence of vascular disease in metabolic syndrome using three proposed definitions.. Int J Cardiol. 117(2), 204-10.
Athyros, V. G., Katsiki N., Tziomalos K., & Karagiannis A. (2011).  Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?. Open Cardiovasc Med J. 5, 226-30.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Preventing macrovascular complications of diabetes: where do we stand with glycemic control?. Expert Opin Investig Drugs. 17(12), 1777-9.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?. Curr Pharm Des. 16(34), 3939-847.
Stavropoulos, K., Imprialos K. P., Katsiki N., Petidis K., Kamparoudis A., Petras P., et al. (2018).  Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. J Clin Hypertens (Greenwich). 20(5), 942-948.
Kakafika, A. I., Athyros V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?. Expert Opin Pharmacother. 9(9), 1437-40.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2014).  Reaching hypertriglyceridemia goals.. Curr Med Res Opin. 30(3), 391-3.
Reklou, A., Doumas M., Imprialos K., Stavropoulos K., Patoulias D., & Athyros V. G. (2018).  Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. Open Cardiovasc Med J. 12, 29-40.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές